BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 22, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ipilimumab: Additional Phase II data

Additional data from the double-blind Phase II 007 trial in 115 patients with Stage III/IV metastatic melanoma showed a 12-month survival rate of 51%. Data were presented at the European Society for...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >